PedAM
Pediatric Disease Annotations & Medicines
| Disease | neutropenia |
| Phenotype | C0006142|breast cancer |
| Sentences | 17 |
| PubMedID- 26122726 | Comparison of ep2006, a filgrastim biosimilar, to the reference: a phase iii, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. |
| PubMedID- 26251780 | The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. |
| PubMedID- 24919931 | Characterization of endogenous g-csf and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling. |
| PubMedID- 25130388 | The goal of this retrospective cohort study was to examine the impact of g-csf prophylaxis and other potential risk factors of severe neutropenia in women with breast cancer. |
| PubMedID- 24888663 | Chemotherapy-induced febrile neutropenia in patients with breast cancer. |
| PubMedID- 26532561 | Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in greece. |
| PubMedID- 23945072 | Conclusion: this study demonstrates that lipegfilgrastim 6 mg is as effective as pegfilgrastim in reducing neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. |
| PubMedID- 20180162 | [pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for germany]. |
| PubMedID- 23320040 | M. c. s. araujo controlled trial of uncaria tomentosa shows that it may be effective in aiding recovery from chemotherapy-induced neutropenia for women with breast cancer. |
| PubMedID- 25556610 | Recent data on the national estimates of mortality rate, length of stay, and health care costs among the subpopulation of febrile neutropenia admissions with breast cancer are lacking. |
| PubMedID- 22123557 | The primary objective of this open-label, two chemotherapy arm, phase 4 study was to evaluate the safety and efficacy of newly developed recombinant granulocyte colony-stimulating factor (rg-csf) used to prevent neutropenia-related complications in patients with metastatic breast cancer treated with docetaxel (75 mg/m(2)) and doxorubicin (50 mg/m(2)) or docetaxel (100 mg/m(2)) alone. |
| PubMedID- 22913768 | We also note, however, that this code has been employed in several single technology appraisals (stas) and evidence review group’s (erg) reports to cost chemotherapy-related febrile neutropenia among adults with her2-negative metastatic breast cancer, adults with chronic lymphocytic leukemia, adults with metastatic prostate cancer, and adults with squamous cell carcinoma of the head and neck, respectively [15-18]. |
| PubMedID- 20361359 | Use of anthracyclines, taxanes or platinums was associated with increased risks of short- (3 months) anemia and neutropenia in patients with breast cancer. |
| PubMedID- 23051869 | Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. |
| PubMedID- 23468242 | Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. |
| PubMedID- 25404882 | Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. |
| PubMedID- 21706156 | Mdm2 snp309 and tp53 r72p associated with severe and febrile neutropenia in breast cancer patients treated with 5-fu/epirubicin/cyclophosphamide. |
Page: 1